Aurobindo Pharma

    AUROPHARMA
    Pharma
    ₹1,571.70
    Price as of 25 Oct 2026, 10:28 pm IST

    Market cap ₹90,432 Cr

    P/E
    24.56
    Day range
    ₹1,547.80 – ₹1,608.80
    52-week range
    ₹1,081.40 – ₹1,740.00
    Volume
    6.50 L
    Open
    ₹1,607.70
    Prev close
    ₹1,610.90

    Latest results · Q1 FY27(consolidated)Revenue ₹9,150 Cr+16.3%Profit ₹1,032 Cr+25.2%Margin 11.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    AUROPHARMA in NSE indices and F&O

    F&O margin for one lot of AUROPHARMA (550 shares)

    Research profile

    Composite 71 / 100

    Factor percentiles

    Value67
    Quality42
    Momentum81
    Low volatility96

    Derived metrics

    Earn. yield
    4.1%
    Graham no.
    ₹968.13
    vs Graham
    -38.4%
    ROE ÷ P/B
    4.0%
    12-1 mom.
    +51.1%
    Return / vol
    1.54
    Magic Formula
    #311
    Piotroski
    2/6
    FCF yield
    2.7%
    PEG
    12.31

    Appears in 12 scans

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 67 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.19 L Cr34.685.0214.8%21.0%29.0%0.06+10.5%
    Divi's LaboratoriesDIVISLAB₹2.38 L Cr81.2114.5216.2%22.0%41.0%0.00+27.8%
    Torrent PharmaTORNTPHARM₹1.72 L Cr76.439.3726.8%15.0%33.0%0.77+50.8%
    Zydus LifesciencesZYDUSLIFE₹1.13 L Cr25.174.2020.1%21.0%24.0%0.46+22.0%
    Apollo HospitalsAPOLLOHOSP₹1.11 L Cr53.1911.5422.6%17.0%16.0%0.90+20.6%
    CiplaCIPLA₹1.08 L Cr32.093.1211.8%15.0%17.0%0.02+2.3%
    Laurus LabsLAURUSLABS₹1.06 L Cr97.3820.0618.2%18.0%32.0%0.48+29.0%
    Aurobindo PharmaAUROPHARMA₹90,432 Cr24.562.479.9%13.0%21.0%0.21+16.3%
    Sector median₹23,579 Cr41.615.6015.1%17.0%25.0%0.16+20.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 12d ago

    Headlines about Aurobindo Pharma from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.

    Key metrics

    P/E (TTM)
    23.9
    EPS (TTM)
    ₹64.00
    Price / Book
    2.41
    ROE (FY26)
    9.9%
    ROCE (latest year)
    13%
    Dividend yield
    0.25%

    Moving averages (NSE)

    20-day
    ₹1,667.09
    Price below
    50-day
    ₹1,663.02
    Price below
    200-day
    ₹1,446.78
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +10.6%
    Profit 3Y CAGR
    +22.0%
    Revenue YoY (Jun 2026)
    +16.3%
    Profit YoY (Jun 2026)
    +25.2%
    Operating margin
    21.0%
    Net margin
    11.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr2.5K Cr5K Cr7.5K Cr10K Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Jun 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-5K Cr-2.5K Cr0 Cr2.5K Cr5K Cr7.5K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr10K Cr20K Cr30K Cr40K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY21FY22FY23FY24FY25FY26₹0₹2₹4₹6₹8

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales7,2197,3527,5807,5677,7967,9798,3827,8688,2868,6468,8539,150
    Expenses5,8465,7535,9205,9496,2306,4016,6226,2656,6086,8737,1037,271
    Operating Profit1,3731,5991,6601,6181,5661,5781,7601,6031,6781,7731,7501,880
    OPM %19%22%22%21%20%20%21%20%20%21%20%21%
    Other Income18816314221136159135107122123117224
    Interest68768911111311811598959398102
    Depreciation418423354404382419444406429465479487
    Profit before tax1,0761,2621,2301,3241,2071,2001,3351,2071,2761,3391,2911,515
    Tax %30%26%26%31%32%30%32%32%34%32%29%32%
    Net Profit7529409079188178469038248489109211,032
    EPS in Rs₹12.92₹15.98₹15.51₹15.69₹14.07₹14.56₹15.56₹14.20₹14.61₹15.67₹15.86₹17.95

    From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days77

    +25 days since Mar 2021

    Inventory Days326

    -7 days since Mar 2021

    Days Payable151

    +48 days since Mar 2021

    Cash Conversion Cycle252

    -30 days since Mar 2021

    Working Capital Days44

    -8 days since Mar 2021

    Strengths, risks & growth

    Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

    Strengths

    None flagged by the checklist.

    Risks

    • The company has delivered a poor sales growth of 6.32% over past five years.
    • Company has a low return on equity of 10.8% over last 3 years.
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    +9%
    5 Years
    +6%
    3 Years
    +11%
    TTM
    +9%

    Compounded Profit Growth

    10 Years
    +6%
    5 Years
    +1%
    3 Years
    +23%
    TTM
    +11%

    Stock Price CAGR

    10 Years
    +7%
    5 Years
    +17%
    3 Years
    +23%
    1 Year
    +45%

    Return on Equity

    10 Years
    +14%
    5 Years
    +10%
    3 Years
    +11%
    Last Year
    +10%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter51.82%51.82%51.88%51.88%0.00 pp
    FII13.95%15.24%16.38%17.41%+1.03 pp
    DII27.66%25.82%25.05%24.37%-0.68 pp
    Government0.03%0.05%0.05%0.05%0.00 pp
    Public6.55%7.08%6.63%6.29%-0.34 pp

    Filed with NSE for Sept 2026: promoters 51.88%, public 48.12% · XBRL filing

    Analysts & fund holdings

    72%
    72% recommend buy
    25 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E24.6 vs 44.2
    Sector P/B5.54
    Beta0.88

    Who holds the shares, quarter by quarter

    Mutual funds 16.31% (-0.40 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters51.9%
    • Foreign institutions17.4%
    • Mutual funds16.3%
    • Insurance4.8%
    • Other domestic institutions3.3%
    • Retail4.7%
    • Others1.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund2.33%2.19%+0.10 pp
    Quant ELSS Tax Saver Fund1.16%8.49%+0.50 pp
    SBI Large & Midcap Fund0.86%1.94%-0.13 pp
    Quant Mid Cap Fund0.85%10.71%+0.30 pp
    Quant Multi Cap Fund0.74%9.49%+0.83 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 275 daily sessions to 23 Oct 2026.

    Computed

    Risk

    Volatility (1Y)
    25.9%
    Downside volatility
    23.7%
    Worst 5% of days
    2.3%
    Average of that tail
    3.4%
    Max drawdown (1Y)
    9.7%
    Below its peak
    9.4%

    Against the market

    Beta vs Nifty 50
    0.39
    Correlation
    0.20
    Relative strength (3M)
    +8.5%
    ATR (14)
    2.8%

    Return

    Return 1M
    -7.5%
    Return 3M
    +3.2%
    Return 6M
    +10.6%
    Return 1Y
    +39.7%
    vs 200-day average
    +8.6%

    Momentum

    RSI (14)
    36.6
    MACD histogram
    -13.61
    Stochastic %K
    14.3
    ADX (14)
    22.5
    +DI / −DI
    8.8 / 26.5
    Money flow index
    39.6

    Participation

    Delivery (20d avg)
    53.7%
    vs its 60-day baseline
    +2.5 pts
    Volume vs 20-day
    -1.0σ
    Close vs day's VWAP
    +0.3%
    52-week position
    76 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹2,422 Cr
    FCF yield
    2.7%
    Cash conversion
    1.58
    Accruals ratio
    -0.035
    Net debt
    ₹881 Cr
    Net debt / equity
    0.02
    EV / sales
    2.61
    PEG
    12.31
    Capex intensity
    9.2%
    Revenue CAGR
    5.6%
    Profit CAGR
    2.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    No market trades
    0 buys · ₹0
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released1,16,35,862₹1267 Cr1 Apr 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge1,67,00,000₹1759 Cr28 Mar 2024
    PAVANKUMAR PS
    Employees/Designated Employees · Market Sale
    		Sell1,000₹10.2 L5 Mar 2024
    CHANDRASEKHAR REDDY KANDATI
    Employees/Designated Employees · Market Sale
    		Sell2,000₹20.9 L1 Mar 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released1,00,50,000₹1049 Cr26 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released23,00,000₹240 Cr26 Feb 2024
    ROOPAK SAWHNEY
    Employees/Designated Employees · Market Sale
    		Sell3,880₹39.2 L16 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge1,34,00,000₹1335 Cr16 Feb 2024
    K BHARATHI
    Other · Market Sale
    		Sell35,000₹3.6 Cr16 Feb 2024
    GITA RAO
    Employees/Designated Employees · Market Sale
    		Sell1,300₹12.8 L16 Feb 2024
    S BALA SUBRAMANYAM REDDY
    Employees/Designated Employees · Market Sale
    		Sell2,000₹20.5 L16 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge2,50,000₹28.0 Cr19 Jan 2024

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • buyback
      Not available — not reported in this filing

      Buy Back

      17 Apr 2026
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      8 Aug 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      26 Aug 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      30 Jul 2024
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      20 Feb 2024
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      20 Nov 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Aug 2023
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      17 Feb 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Jul 2022
      ex-date
    • dividend
      ₹4.50

      Interim Dividend - Rs 4.50 Per Share

      6 Jun 2022
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      18 Feb 2022
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      17 Nov 2021
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      27 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Aug 2021
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      22 Feb 2021
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      23 Nov 2020
      ex-date
    • dividend
      ₹1.25

      Annual General Meeting/Interim Dividend - Rs 1.25 Per Share

      21 Aug 2020
      ex-date
    • dividend
      ₹1.75

      Interim Dividend - Rs 1.75 Per Share

      17 Feb 2020
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      21 Nov 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Aug 2019
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Submission of Notice published in newspapers.

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.

    Company Update
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

    Intimation of completion of acquisition.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Intimation of acquisition of a step down subsidiary in USA.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.

    Company Update
    Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of closure of trading window.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor Analyst meet scheduled on 24.09.2026.

    Company Update
    Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company

    Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Intimation of subscription of 10,000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.

    Company Update
    Completion Of US FDA Inspection At Unit-IV Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company

    Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor / analyst meet scheduled on 22.09.2026.

    Filed with BSE (scrip 524804); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Final order

      Final Order in the matter of Aurobindo Pharma Ltd [SAT Appeal No.: 23/2021 & Misc. App. No. 559/2020]

      4 Aug 2020
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Mr. PV Ramprasad Reddy, Mrs. P. Suneela Rani, Mr. Kambam P Reddy, Trident Chemphar Ltd., Veritaz Health Care Ltd., Top Class Capital Markets Pvt. Ltd. and Aurobindo Pharma Ltd. in the matter of Aurobindo Pharma Ltd. [SAT Appeal No.: 559/2019] [SAT Appeal No.: 31/2020 & Misc. App. No. 38/2020]

      23 Sept 2019
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Sumanth Kumar Reddy Mettu (in the matter of Aurobindo Pharma Ltd)

      22 May 2017
      Read on SEBI
    • Adjudication order

      Adjudication order against Brijwasi Securities Private Limited in the matter of Aurobindo Pharma Limited

      27 Aug 2009
      Read on SEBI
    • Order

      Order in the matter of Aurobindo Pharma Limited

      13 Oct 2008
      Read on SEBI

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Aurobindo Pharma: common questions

    Answered from the figures on this page.

    Aurobindo Pharma last traded at ₹1,571.70 (NSE, as of 25 Oct 2026). The last session moved it down 2.43%.

    Aurobindo Pharma is valued at about ₹90,432 crore (NSE, as of 25 Oct 2026).

    Aurobindo Pharma trades at a price-to-earnings ratio of 24.56 (NSE, as of 25 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Aurobindo Pharma has traded between ₹1,081.40 and ₹1,740.00 over the past 52 weeks, to 25 Oct 2026. It is currently 74% of the way up that range.

    Aurobindo Pharma (AUROPHARMA) is classified under Pharma on this site's screener.